Breast Cancer
October 2010
This bulletin covers aspects of breast cancer, and should be of interest to multidisciplinary teams
working in this area.
Sections can include:
 Combined Modality Therapies
 Drug Therapy
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Supportive Care & Symptom Management
 Surgery
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you
would like to request a print copy, please submit your request online at
www.gglss.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is
not intended to be comprehensive. Professional judgment should be exercised when appraising
the material. The Library takes no responsibility for the wording, content and accuracy of the
information supplied, which has been extracted in good faith from reputable sources. NHSGGC is
not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Specialist Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
1
Breast Cancer, October 2010
Kirsty Coltart, Specialist Librarian, NHSGGC Library Network
COMBINED MODALITY THERAPIES
Adkison JB. Kuske RR. Patel RR. Breast conserving surgery and accelerated partial breast
irradiation after prior breast radiation therapy. American Journal of Clinical Oncology. 33(5):427-31,
2010 Oct.
Balduzzi A. Leonardi MC. Cardillo A. Timing of adjuvant systemic therapy and radiotherapy after
breast-conserving surgery and mastectomy. Cancer Treatment Reviews. 36(6):443-50, 2010 Oct.
Del Turco MR. Ponti A. Bick U. Quality indicators in breast cancer care. European Journal of
Cancer. 46(13):2344-56, 2010 Sep.
Gomez-Raposo C. Zambrana Tovar F. Sereno Moyano M. Male breast cancer. Cancer Treatment
Reviews. 36(6):451-7, 2010 Oct.
Sawaki M. Iwata H. Sato Y. Phase II study of preoperative systemic treatment with the
combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing
breast cancer. Breast. 19(5):370-6, 2010 Oct.
Vaidya JS. Joseph DJ. Tobias JS. Targeted intraoperative radiotherapy versus whole breast
radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, noninferiority phase 3 trial.[Erratum appears in Lancet. 2010 Jul 10;376(9735):90] Lancet.
376(9735):91-102, 2010 Jul 10.
DRUG THERAPY
Alba E. Ruiz-Borrego M. Margeli M. Maintenance treatment with pegylated liposomal doxorubicin
versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 200101 study. Breast Cancer Research & Treatment. 122(1):169-76, 2010 Jul.
Alvarez RH. Valero V. Hortobagyi GN. Emerging targeted therapies for breast cancer. Journal of
Clinical Oncology. 28(20):3366-79, 2010 Jul 10.
Amir E. Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in
metastatic breast cancer. Cancer Treatment Reviews. 36(5):410-5, 2010 Aug.
Blohmer JU. Schmid P. Hilfrich J. Epirubicin and cyclophosphamide versus epirubicin and
docetaxel as first-line therapy for women with metastatic breast cancer: final results of a
randomised phase III trial. Annals of Oncology. 21(7):1430-5, 2010 Jul.
Boussen H. Cristofanilli M. Zaks T. Phase II study to evaluate the efficacy and safety of
neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. Journal of Clinical
Oncology. 28(20):3248-55, 2010 Jul 10.
Burstein HJ. Prestrud AA. Seidenfeld J. American Society of Clinical Oncology clinical practice
guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast
cancer. Journal of Clinical Oncology. 28(23):3784-96, 2010 Aug 10.
Cameron D. Casey M. Oliva C. Lapatinib plus capecitabine in women with HER-2-positive
advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist.
15(9):924-34, 2010.
Ciruelos EM. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast
cancer: a multicenter phase II study (SOLTI 0301 trial). Annals of Oncology. 21(7):1442-7, 2010
Jul.
Conlin AK. Seidman AD. Bach A. Phase II trial of weekly nanoparticle albumin-bound paclitaxel
with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing
metastatic breast cancer. Clinical Breast Cancer. 10(4):281-7, 2010 Aug 1.
2
Breast Cancer, October 2010
Kirsty Coltart, Specialist Librarian, NHSGGC Library Network
Cortes J. Vahdat L. Blum JL. Phase II study of the halichondrin B analog eribulin mesylate in
patients with locally advanced or metastatic breast cancer previously treated with an anthracycline,
a taxane, and capecitabine. Journal of Clinical Oncology. 28(25):3922-8, 2010 Sep 1.
Giovannini M. Aldrighetti D. Zucchinelli P. Antiangiogenic strategies in breast cancer
management. Critical Reviews in Oncology-Hematology. 76(1):13-35, 2010 Oct.
Hortobagyi GN. Gomez HL. Li RK. Analysis of overall survival from a phase III study of
ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines
and taxanes. Breast Cancer Research & Treatment. 122(2):409-18, 2010 Jul.
Manga GP. Shahi PK. Urena MM. Phase II study of neoadjuvant treatment with doxorubicin,
docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer. Breast
Cancer. 17(3):205-11, 2010 Jul.
Mansi JL. Yellowlees A. Lipscombe J. Five-year outcome for women randomised in a phase III
trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary
medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. Breast
Cancer Research & Treatment. 122(3):787-94, 2010 Aug.
Miles DW. Chan A. Dirix LY. Phase III study of bevacizumab plus docetaxel compared with
placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2negative metastatic breast cancer. Journal of Clinical Oncology. 28(20):3239-47, 2010 Jul 10.
Morrow PK. Divers S. Provencher L. Phase II study evaluating the efficacy and safety of
sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following
chemotherapy. Breast Cancer Research & Treatment. 123(3):837-42, 2010 Oct.
Palmieri C. Krell J. James CR. Rechallenging with anthracyclines and taxanes in metastatic
breast cancer. Nature Reviews Clinical Oncology. 7(10):561-74, 2010 Oct.
Pierga JY. Delaloge S. Espio M. A multicenter randomized phase II study of sequential
epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab
according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Breast Cancer Research & Treatment. 122(2):429-37, 2010 Jul.
Pritchard KI. Rolski J. Papai Z. Results of a phase II study comparing three dosing regimens of
fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer
Research & Treatment. 123(2):453-61, 2010 Sep.
Procter M. Suter TM. de Azambuja E. Longer-term assessment of trastuzumab-related cardiac
adverse events in the Herceptin Adjuvant (HERA) trial. Journal of Clinical Oncology. 28(21):34228, 2010 Jul 20.
Riemsma R. Forbes CA. Kessels A. Systematic review of aromatase inhibitors in the first-line
treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Research &
Treatment. 123(1):9-24, 2010 Aug.
Sanchez-Munoz, A. Is it Possible to Increase pCR in the Neoadjuvant Treatment With a DoseDense/Sequential Combination?: Results From a Phase II Trial Combining Epirubicin and
Cyclophosphamide Followed by Paclitaxel and Gemcitabine; Trastuzumab in Stage II and III Breast
Cancer Patients. American Journal of Clinical Oncology. 33(5):432-7, 2010 Oct.
Seruga B. Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a
meta-analysis. Breast Cancer Research & Treatment. 122(3):609-17, 2010 Aug.
Sirohi B. A'Hern R. Coombes G. A randomised comparative trial of infusional ECisF versus
conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Annals of
Oncology. 21(8):1623-9, 2010 Aug.
Smith LA. Cornelius VR. Plummer CJ. Cardiotoxicity of anthracycline agents for the treatment of
cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 10:337,
2010.
3
Breast Cancer, October 2010
Kirsty Coltart, Specialist Librarian, NHSGGC Library Network
Sparano JA. Vrdoljak E. Rixe O. Randomized phase III trial of ixabepilone plus capecitabine
versus capecitabine in patients with metastatic breast cancer previously treated with an
anthracycline and a taxane. Journal of Clinical Oncology. 28(20):3256-63, 2010 Jul 10.
Toppmeyer DL. Goodin S. Ixabepilone, a new treatment option for metastatic breast cancer.
American Journal of Clinical Oncology. 33(5):516-21, 2010 Oct.
Tutt A. Robson M. Garber JE. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with
BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet.
376(9737):235-44, 2010 Jul 24.
Valachis A. Polyzos NP. Patsopoulos NA. Bevacizumab in metastatic breast cancer: a metaanalysis of randomized controlled trials. Breast Cancer Research & Treatment. 122(1):1-7, 2010
Jul.
Venturini M. Bighin C. Puglisi F. A multicentre Phase II study of non-pegylated liposomal
doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast
cancer. Breast. 19(5):333-8, 2010 Oct.
Wildiers H. Fontaine C. Vuylsteke P. Multicenter phase II randomized trial evaluating
antiangiogenic therapy with sunitinib as consolidation after objective response to taxane
chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Research &
Treatment. 123(2):463-9, 2010 Sep.
Yardley DA. Zubkus J. Daniel B. A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine,
Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With
Locally Advanced Breast Cancer. Clinical Breast Cancer. 10(5):367-72, 2010 Oct 1.
PATHOLOGY, STAGING, POLYMORPHISMS, BIOMARKERS
Fan Y. Wang J. Yang Y. Detection and identification of potential biomarkers of breast cancer.
Journal of Cancer Research & Clinical Oncology. 136(8):1243-54, 2010 Aug.
Hammond ME. Hayes DF. Dowsett M. American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for immunohistochemical testing of estrogen
and progesterone receptors in breast cancer (unabridged version). Archives of Pathology &
Laboratory Medicine. 134(7):e48-72, 2010 Jul.
Hodgkinson VC. Eagle GL. Drew PJ. Biomarkers of chemotherapy resistance in breast cancer
identified by proteomics: current status. Cancer Letters. 294(1):13-24, 2010 Aug 1.
Lebeau A. Turzynski A. Braun S. Reliability of human epidermal growth factor receptor 2
immunohistochemistry in breast core needle biopsies. Journal of Clinical Oncology. 28(20):326470, 2010 Jul 10.
Nguyen NP. Almeida FS. Chi A. Molecular biology of breast cancer stem cells: potential clinical
applications. Cancer Treatment Reviews. 36(6):485-91, 2010 Oct.
Vera-Ramirez L. Sanchez-Rovira P. Ramirez-Tortosa CL. Gene-expression profiles, tumor
microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated
approach. Cancer Treatment Reviews. 36(6):477-84, 2010 Oct.
PROGNOSIS, SURVIVAL, RISK FACTORS
Harlan LC. Breast cancer in men in the United States: a population-based study of diagnosis,
treatment, and survival. Cancer. 116(15):3558-68, 2010 Aug 1.
Protani M. Coory M. Martin JH. Effect of obesity on survival of women with breast cancer:
4
Breast Cancer, October 2010
Kirsty Coltart, Specialist Librarian, NHSGGC Library Network
systematic review and meta-analysis. Breast Cancer Research & Treatment. 123(3):627-35, 2010
Oct.
RADIOTHERAPY AND IMAGING
Beitsch P. Vicini F. Keisch M. Five-year outcome of patients classified in the unsuitable; category
using the American Society of Therapeutic Radiology and Oncology (ASTRO) Consensus Panel
guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated
on the American Society of Breast Surgeons MammoSite; Registry trial. Annals of Surgical
Oncology. 17(Suppl 3):219-25, 2010 Oct.
Mehta VK. Experience with an electronic brachytherapy technique for intracavitary accelerated
partial breast irradiation. American Journal of Clinical Oncology. 33(4):327-35, 2010 Aug.
Peare R. Staff RT. Heys SD. The use of FDG-PET in assessing axillary lymph node status in
breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Research
&Treatment. 123(1):281-90, 2010 Aug.
Salz T. Richman AR. Brewer NT. Meta-analyses of the effect of false-positive mammograms on
generic and specific psychosocial outcomes. Psycho-Oncology. 19(10):1026-34, 2010 Oct.
Shaitelman SF. Vicini FA. Beitsch P. Haffty B. Keisch M. Lyden M. Five-year outcome of
patients classified using the American Society for Radiation Oncology consensus statement
guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated
on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer. 116(20):4677-85,
2010 Oct 15.
Vicini F. Winter K. Wong J. Initial efficacy results of RTOG 0319: three-dimensional conformal
radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/ II breast
carcinoma. International Journal of Radiation Oncology, Biology, Physics. 77(4):1120-7, 2010 Jul
15.
Yuan Y. Chen XS. Liu SY. Accuracy of MRI in prediction of pathologic complete remission in
breast cancer after preoperative therapy: a meta-analysis. AJR. American Journal of
Roentgenology. 195(1):260-8, 2010 Jul.
SUPPORTIVE CARE AND SYMPTOM MANAGEMENT
Andrykowski MA. Burris JL. Walsh E. Attitudes toward information about genetic risk for cognitive
impairment after cancer chemotherapy: breast cancer survivors compared with healthy controls.
Journal of Clinical Oncology. 28(21):3442-7, 2010 Jul 20.
Beaver K. Williamson S. Chalmers K. Telephone follow-up after treatment for breast cancer: views
and experiences of patients and specialist breast care nurses. Journal of Clinical Nursing. 19(1920):2916-24, 2010 Oct.
Bernardo LM. Abt KL. Ren D. Self-reported exercise during breast cancer treatment: results of a
national survey. Cancer Nursing. 33(4):304-9, 2010 Jul-Aug.
Brown JE. Cook RJ. Lipton A. Prognostic factors for skeletal complications from metastatic bone
disease in breast cancer. Breast Cancer Research &Treatment. 123(3):767-79, 2010 Oct.
Chan DN. Lui LY. So WK. Effectiveness of exercise programmes on shoulder mobility and
lymphoedema after axillary lymph node dissection for breast cancer: systematic review.
Journal of Advanced Nursing. 66(9):1902-14, 2010 Sep.
Emilee G. Ussher JM. Perz J. Sexuality after breast cancer: a review. Maturitas. 66(4):397-407,
2010 Aug.
Enderlin CA. Coleman EA. Cole C. Sleep across chemotherapy treatment: a growing concern for
women older than 50 with breast cancer. Oncology Nursing Forum. 37(4):461-A3, 2010 Jul.
5
Breast Cancer, October 2010
Kirsty Coltart, Specialist Librarian, NHSGGC Library Network
Gosselin TK. Schneider SM. Plambeck MA. A prospective randomized, placebo-controlled skin
care study in women diagnosed with breast cancer undergoing radiation therapy. Oncology Nursing
Forum. 37(5):619-26, 2010 Sep 1.
Hickey M. Emery LI. Gregson J. The multidisciplinary management of menopausal symptoms
after breast cancer: a unique model of care. Menopause. 17(4):727-33, 2010 Jul.
Lee SA. Kang JY. Kim YD. Effects of a scapula-oriented shoulder exercise programme on upper
limb dysfunction in breast cancer survivors: a randomized controlled pilot trial. Clinical
Rehabilitation. 24(7):600-13, 2010 Jul.
Low CA. Stanton AL. Bower JE. A randomized controlled trial of emotionally expressive writing for
women with metastatic breast cancer. Health Psychology. 29(4):460-6, 2010 Jul.
McNeely ML. Campbell K. Ospina M. Exercise interventions for upper-limb dysfunction due to
breast cancer treatment. Cochrane Database of Systematic Reviews. 6:CD005211, 2010.
Marcus AC. Garrett KM. Cella D. Can telephone counseling post-treatment improve psychosocial
outcomes among early stage breast cancer survivors?. Psycho-Oncology. 19(9):923-32, 2010 Sep.
Park K. Choi KS. Kye SY. Unwanted effects of risk notification for breast cancer regarding
intention toward mammography utilization. Psycho-Oncology. 19(8):823-9, 2010 Aug.
Pedersen AE. Sawatzky JA. Hack TF. The sequelae of anxiety in breast cancer: a human
response to illness model. Oncology Nursing Forum. 37(4):469-75, 2010 Jul.
Pronzato P. Cortesi E. van der Rijt CC. Epoetin alfa improves anemia and anemia-related,
patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy:
results of a European, multicenter, randomized, controlled trial. Oncologist. 15(9):935-43, 2010.
Rada G. Capurro D. Pantoja T. Non-hormonal interventions for hot flushes in women with a
history of breast cancer. Cochrane Database of Systematic Reviews. 9:CD004923, 2010.
Speed-Andrews AE. Stevinson C. Belanger LJ. Pilot evaluation of an Iyengar yoga program for
breast cancer survivors. Cancer Nursing. 33(5):369-81, 2010 Sep-Oct.
Tiedtke C. de Rijk A. Dierckx de Casterle B. Experiences and concerns about 'returning to work'
for women breast cancer survivors: a literature review. Psycho-Oncology. 19(7):677-83, 2010 Jul.
Tomao F. Spinelli GP. Panici PB. Ovarian function, reproduction and strategies for fertility
preservation after breast cancer. Critical Reviews in Oncology-Hematology. 76(1):1-12, 2010 Oct.
Voskuil DW. van Nes JG. Junggeburt JM. Maintenance of physical activity and body weight in
relation to subsequent quality of life in postmenopausal breast cancer patients. Annals of Oncology.
21(10):2094-101, 2010 Oct.
Wanchai A. Armer JM. Stewart BR. Complementary and alternative medicine use among women
with breast cancer: a systematic review. Clinical Journal of Oncology Nursing. 14(4):E45-55, 2010
Aug.
Warren M. Uncertainty, lack of control and emotional functioning in women with metastatic breast
cancer: a review and secondary analysis of the literature using the critical appraisal technique.
European Journal of Cancer Care. 19(5):564-74, 2010 Sep.
Wefel JS. Saleeba AK. Buzdar AU. Acute and late onset cognitive dysfunction associated with
chemotherapy in women with breast cancer. Cancer. 116(14):3348-56, 2010 Jul 15.
SURGERY
Berry MG. Oncoplastic breast surgery: a review and systematic approach. Journal of Plastic,
Reconstructive & Aesthetic Surgery: JPRAS. 63(8):1233-43, 2010 Aug.
6
Breast Cancer, October 2010
Kirsty Coltart, Specialist Librarian, NHSGGC Library Network
Giard S. Chauvet MP. Penel N. Feasibility of sentinel lymph node biopsy in multiple unilateral
synchronous breast cancer: results of a French prospective multi-institutional study (IGASSU
0502). Annals of Oncology. 21(8):1630-5, 2010 Aug.
Glynn RW. Williams L. Dixon JM. A further survey of surgical management of the axilla in UK
breast cancer patients. Annals of the Royal College of Surgeons of England. 92(6):506-11, 2010
Sep.
Kydd LA. Reid SA. Adams J. The Breast Surgery Gallery: an educational and counseling tool for
people with breast cancer or having prophylactic breast surgery. Clinical Journal of Oncology
Nursing. 14(5):643-8, 2010 Oct 1.
Land SR. Kopec JA. Julian TB. Patient-reported outcomes in sentinel node-negative adjuvant
breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical
Adjuvant Breast and Bowel Project phase III protocol B-32. Journal of Clinical Oncology.
28(25):3929-36, 2010 Sep 1.
Please note that the journal articles you are accessing may be protected by copyright legislation so
there may be a limit on the number of articles you can download or print from any single issue of a
journal. If you obtain a copy via your local library's document request service, you may be required
to complete a copyright declaration form. Consult your local library with any queries, or for further
information see the website of the Copyright Licensing Agency at www.cla.co.uk.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin :
OVID MEDLINE and MEDLINE in process, local journal collection
7
Breast Cancer, October 2010
Kirsty Coltart, Specialist Librarian, NHSGGC Library Network